Canada: Federal Court Addresses The Intention And Application Of Vanessa's Law

The Federal Court of Canada has addressed how the Protecting Canadians from Unsafe Drugs Act (Vanessa's Law) should be applied in its decision in Peter Doshi v. Attorney General of Canada released on July 9.

What You Need To Know

  • Federal Court of Canada held that section 21.1(3) of the Food and Drugs Act, enacted as part of Vanessa's Law, allows a scientific researcher to obtain from Health Canada clinical trial information contained in regulatory submissions after the submission has been reviewed and a drug product has been granted marketing authorization, or if the submission is rejected or withdrawn.
  • The Court found that Heath Canada's current blanket policy of maintaining clinical data as confidential business information was inconsistent with the purpose of Vanessa's Law, which is to improve transparency of clinical trials, and contravenes the right to freedom of expression under section 2(b) of the Charter.
  • The Court specifically contemplated that the Minister of Health could enact regulations permitted under Vanessa's Law to change this outcome. However, none have been enacted at this time. Health Canada has instead put out draft regulations1 that would expressly allow for publication of clinical trial data once a drug has been approved for marketing, or subject to a final rejection. So it is unlikely any restriction on disclosure under Vanessa's Law will be enacted.
  • If this decision is not reversed on appeal, drug manufacturers will not have any assurances their clinical trial information will remain confidential indefinitely.

Background on Vanessa's Law

Vanessa's Law permits Health Canada to provide confidential business information, which could include unpublished clinical trial data submitted by a drug manufacturer in a regulatory submission, to scientific researchers who carry out "functions relating to the protection or promotion of human health or safety of the public."

Vanessa's Story

Vanessa's Law was enacted after 15 year-old Vanessa Young died of a heart attack after taking certain prescription medication. Her father, Terence Young, was elected to Parliament and was the driving force behind Vanessa's Law—an amendment to the Food and Drugs Act—which was intended to make regulatory information about pharmaceuticals (including clinical trial information) more accessible to scientists. As a result, section 21.1(3) permits the Minister of Health to disclose confidential business information about a therapeutic product without notifying the sponsor of the product if the disclosure is intended to promote or protect human health and safety, and is directed to particular individuals, including a person who carries out functions relating to the protection or promotion of human health, or the safety of the public.

Dr. Doshi and the Application of Vanessa's Law

Dr. Peter Doshi, an Assistant Professor at the University of Maryland, asked Health Canada under Vanessa's Law for particular scientific information regarding a number of different and approved drugs. He was seeking the information to conduct a Cochrane review—a complex meta-analysis—of all available clinical information regarding two particular classes of medicines (HPV vaccines and anti-viral medications).

Health Canada was willing to provide Dr. Doshi with the requested information but, consistent with its current practice, required him to sign a confidentiality agreement. He refused to do so and in the process brought an application for judicial review asking the Federal Court to require Health Canada to provide the information by an order for mandamus.

Justice Grammond of the Federal Court allowed the application for judicial review and issued an order requiring Health Canada to provide Dr. Doshi with the requested information. He found that Health Canada's decision to simply follow their pre-Vanessa's Law practice of always requiring a confidentiality agreement was inconsistent with a key statutory purpose of Vanessa's Law, which was to improve transparency of clinical trials. In addition, by imposing a blanket policy of confidentiality, without any real consideration of the facts of this case, Health Canada improperly fettered its discretion. Justice Grammond also found that a requirement of confidentiality unduly burdened Dr. Doshi's constitutional right to freedom of expression.

While the typical remedy for an improper exercise of discretion is to quash the decision and send it back to the decision-maker for reconsideration, Justice Grammond held that the case was sufficiently exceptional that he should simply order Health Canada to release the materials to Dr. Doshi. While it is not clear whether the information has yet been released, absent a reversal on appeal, its release appears inevitable.

The Future for Pharmaceutical Companies

This case raises some significant questions for pharmaceutical companies. While companies have long taken the confidentiality of clinical trials for granted, unless the Minister introduces new regulations, it appears as if Vanessa's Law may well result in their disclosure to scientists and other researchers without any obligations of confidentiality. Moreover, it appears that the courts will not hesitate to apply s. 2(b) of the Charter to attempts by Health Canada to insist on confidentiality.

As a practical matter, Health Canada intends to begin releasing clinical trial data submitted with a drug submission once the drug has been approved or subject to a final rejection during review. This approach is consistent with the current process in the U.S. and EU. Draft regulations have been published and are expected to come into force later this year. Nevertheless, the industry should encourage to ensure a balance is struck between protecting confidential business information and protecting the public, so implementation of these new regulations as well as future disclosures under Vanessa's Law, do not compromise manufacturer's proprietary information.


1 See

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions